vTv Therapeutics Inc. financial data

Symbol
VTVT on Nasdaq
Industry
Pharmaceutical Preparations
Location
3980 Premier Dr, Suite 310, High Point, NC
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 20, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 658 % +360%
Debt-to-equity 160 %
Return On Equity -93.9 % -209%
Return On Assets -40.6 % +61.3%
Operating Margin -2.38K %

Shares

Label TTM Value / Value Unit Change %
Entity Public Float 23.2M USD +1.14%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 1.02M USD
Research and Development Expense 11.5M USD -15.1%
General and Administrative Expense 13.7M USD +14.6%
Operating Income (Loss) -24.2M USD +5.18%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -22.6M USD +12.9%
Income Tax Expense (Benefit) 100K USD
Net Income (Loss) Attributable to Parent -18.5M USD +8.83%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 36.7M USD +289%
Accounts Receivable, after Allowance for Credit Loss, Current 62K USD -39.2%
Assets, Current 38.1M USD +258%
Property, Plant and Equipment, Net 28K USD -76.1%
Operating Lease, Right-of-Use Asset 125K USD -48.8%
Assets 38.3M USD +247%
Accounts Payable, Current 939K USD -77%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 5.2M USD -51.1%
Contract with Customer, Liability, Noncurrent 18.7M USD 0%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 24M USD -18.9%
Retained Earnings (Accumulated Deficit) -300M USD -6.65%
Stockholders' Equity Attributable to Parent 12.2M USD
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 14.3M USD
Liabilities and Equity 38.3M USD +247%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.34M USD -42%
Net Cash Provided by (Used in) Financing Activities 50.1M USD +325%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 42.8M USD +545%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 36.7M USD +289%
Deferred Tax Assets, Valuation Allowance 34M USD +17.2%
Deferred Tax Assets, Gross 34M USD +17.2%
Operating Lease, Liability 169K USD -50%
Depreciation 22K USD 0%
Lessee, Operating Lease, Liability, to be Paid 177K USD -52.3%
Property, Plant and Equipment, Gross 536K USD -11.3%
Operating Lease, Liability, Current 169K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Two 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year One 177K USD -8.76%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 8K USD -75.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 0 USD
Deferred Tax Assets, Operating Loss Carryforwards 27.8M USD +17.3%
Preferred Stock, Shares Authorized 50M shares
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 0 USD
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 2.76M USD +74.7%
Interest Expense 13K USD -13.3%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares